Bohets H, Lavrijsen K, Hendrickx J, van Houdt J, van Genechten V, Verboven P, Meuldermans W, Heykants J
Janssen Research Foundation, Department of Pharmacokinetics, Turnhoutseweg 30, B-2340 Beerse, Belgium.
Br J Pharmacol. 2000 Apr;129(8):1655-67. doi: 10.1038/sj.bjp.0703246.
Cisapride is a prokinetic drug that is widely used to facilitate gastrointestinal tract motility. Structurally, cisapride is a substituted piperidinyl benzamide that interacts with 5-hydroxytryptamine-4 receptors and which is largely without central depressant or antidopaminergic side-effects. The aims of this study were to investigate the metabolism of cisapride in human liver microsomes and to determine which cytochrome P-450 (CYP) isoenzyme(s) are involved in cisapride biotransformation. Additionally, the effects of various drugs on the metabolism of cisapride were investigated. The major in vitro metabolite of cisapride was formed by oxidative N-dealkylation at the piperidine nitrogen, leading to the production of norcisapride. By using competitive inhibition data, correlation studies and heterologous expression systems, it was demonstrated that CYP3A4 was the major CYP involved. CYP2A6 also contributed to the metabolism of cisapride, albeit to a much lesser extent. The mean apparent K(m) against cisapride was 8.6+/-3.5 microM (n = 3). The peak plasma levels of cisapride under normal clinical practice are approximately 0.17 microM; therefore it is unlikely that cisapride would inhibit the metabolism of co-administered drugs. In this in vitro study the inhibitory effects of 44 drugs were tested for any effect on cisapride biotransformation. In conclusion, 34 of the drugs are unlikely to have a clinically relevant interaction; however, the antidepressant nefazodone, the macrolide antibiotic troleandomycin, the HIV-1 protease inhibitors ritonavir and indinavir and the calcium channel blocker mibefradil inhibited the metabolism of cisapride and these interactions are likely to be of clinical relevance. Furthermore, the antimycotics ketoconazole, miconazole, hydroxy-itraconazole, itraconazole and fluconazole, when administered orally or intravenously, would inhibit cisapride metabolism.
西沙必利是一种促动力药物,广泛用于促进胃肠道蠕动。在结构上,西沙必利是一种取代的哌啶基苯甲酰胺,它与5-羟色胺-4受体相互作用,并且基本上没有中枢抑制或抗多巴胺能副作用。本研究的目的是研究西沙必利在人肝微粒体中的代谢,并确定哪些细胞色素P-450(CYP)同工酶参与西沙必利的生物转化。此外,还研究了各种药物对西沙必利代谢的影响。西沙必利的主要体外代谢产物是通过哌啶氮上的氧化N-去烷基化形成的,导致去甲西沙必利的产生。通过使用竞争性抑制数据、相关性研究和异源表达系统,证明CYP3A4是主要参与的CYP。CYP2A6也参与了西沙必利的代谢,尽管程度要小得多。对西沙必利的平均表观K(m)为8.6±3.5微摩尔(n = 3)。在正常临床实践中,西沙必利的血浆峰值水平约为0.17微摩尔;因此,西沙必利不太可能抑制同时服用药物的代谢。在这项体外研究中,测试了44种药物对西沙必利生物转化的抑制作用。总之,34种药物不太可能产生具有临床意义的相互作用;然而,抗抑郁药奈法唑酮、大环内酯类抗生素醋竹桃霉素、HIV-1蛋白酶抑制剂利托那韦和茚地那韦以及钙通道阻滞剂米贝拉地尔抑制了西沙必利的代谢,这些相互作用可能具有临床意义。此外,抗真菌药酮康唑、咪康唑、羟基伊曲康唑、伊曲康唑和氟康唑,口服或静脉给药时,会抑制西沙必利的代谢。